Clearance Summary
RANDOX BILIRUBIN received FDA 510(k) clearance under submission number K973995, sponsored by Randox Laboratories, Ltd.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Hematology review panel. The statutory decision date of record is 1997-12-08.
- Submission: K973995
- Applicant / Sponsor: Randox Laboratories, Ltd.
- Clearance pathway: Traditional
- Review panel: Hematology
- Device class: Class II
- Regulation citation: 21 CFR 864.7500
- Decision date: 1997-12-08
Classification & Regulation
This clearance is catalogued under FDA product code GIG and 21 CFR 864.7500, within the Hematology review panel as a Class II device.